A new novolimus-eluting bioresorbable coronary scaffold: Present status and future clinical perspectives

Nef HM, Wiebe J, Foin N, Blachutzik F, Doerr O, Toyloy S, Hamm CW (2017)


Publication Type: Journal article

Publication year: 2017

Journal

Book Volume: 227

Pages Range: 127-133

DOI: 10.1016/j.ijcard.2016.11.033

Abstract

The DESolve® scaffold (Elixir Medical Corporation, Sunnyvale, California, USA) is manufactured from a poly-l-lactide based polymer and elutes an anti-proliferative, anti-inflammatory drug, Novolimus from a poly-l-lactide based topcoat mixture. The strut thickness is 150μm and the scaffold has platinum-iridium radiopaque markers at both ends. Radial support is available during the early time period to prevent recoil. The scaffold biodegrades within 1year (>90% reduction in molecular weight) and then completely bioresorbs within 2years. The DESolve® scaffold permits a wide range of expansion with a consequently reduced risk for strut fracture. Lumen and scaffold enlargement is observed within 3-6months in both preclinical and clinical studies potentially allowing for the scaffolded region to respond to vasoactive stimuli. The device has a unique property of self-correction observed in bench top studies, which in clinical practice has the potential to eliminate minor malapposition following deployment.

Involved external institutions

How to cite

APA:

Nef, H.M., Wiebe, J., Foin, N., Blachutzik, F., Doerr, O., Toyloy, S., & Hamm, C.W. (2017). A new novolimus-eluting bioresorbable coronary scaffold: Present status and future clinical perspectives. International Journal of Cardiology, 227, 127-133. https://doi.org/10.1016/j.ijcard.2016.11.033

MLA:

Nef, Holger M., et al. "A new novolimus-eluting bioresorbable coronary scaffold: Present status and future clinical perspectives." International Journal of Cardiology 227 (2017): 127-133.

BibTeX: Download